1-2 of 2
Tiffany Juarez, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia

Michael Y. Choi, MD, George F. Widhopf, II, PhD, Jian Yu, PhD, Reilly L Kidwell, BS, BA, CCRC, Laura Z. Rassenti, PhD, Charlene Gutierrez, Susette Gorak, Tiffany Juarez, PhD, Emily Pittman, PhD, Hongying Li, PhD, Karen Messer, PhD, Charles Prussak, PhD, Januario E. Castro, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2016) 128 (22): 3224.
https://doi.org/10.1182/blood.V128.22.3224.3224
Published: 2016
Journal Articles

Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts

Michael Y. Choi, MD, George F. Widhopf, II, PhD, Januario Castro, MD, Hongying Li, PhD, Reilly L Kidwell, BS, BA, CCRC, Sam C Zhang, B.A., Tiffany Juarez, PhD, Susette Gorak, Laura Z. Rassenti, PhD, Karen Messer, PhD, Charles Prussak, PhD, Catriona HM Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1736.
https://doi.org/10.1182/blood.V126.23.1736.1736
Published: 2015